A meeting of the Board of Directors of Sattva Sukun Lifecare Limited was held on Tuesday, June 30th, 2026, commencing at 01:35 PM and concluding at 02:15 PM at the company's registered office at Office No. 101 on 1st Floor, Crystal Rose C.H.S Datta Mandir Road, Mahavir Nagar, Kandivali West, Mumbai 400067.

The Board transacted the following matters:

1. & 2. Appointment of Directors

The Board considered and approved the regularization of two directors, subject to shareholder approval in an upcoming General Meeting:

  • Mr. Sachin Bhanubhai Manseta (DIN: 03471126) was approved for appointment as a Non-Executive, Independent Director. His term is proposed to be effective from July 22, 2026, for a period of 5 years. His brief profile describes him as a professional with experience in secretarial and legal matters. He holds directorships in 14 other entities, including Serenius Ventures Private Limited and Anand Property Finance Ltd. The company affirms he is not debarred from holding the office of director.
  • Mr. Chirag Dedhia (DIN: 08583331) was approved for appointment as a Non-Executive, Non-Independent Director. His term is also proposed to be effective from July 22, 2026, for 5 years. His profile states he is a finance professional with a Master's degree in Finance from the University of Surrey and a B.Com from Mithibai College, Mumbai. He holds directorships in three other entities: Truestar Enterprise Private Limited, Yummzo Snacks And Drinks Llp, and Nyvaan Advisory Llp. The company affirms he is not debarred from holding the office of director.

3. Change of Company Name

The Board considered and approved a change of the company's name from "Sattva Sukun Lifecare Limited" to one of the following options: "Tavexia Lifecare Limited", "Trumaxa Lifecare Limited", "Trustarex Lifecare Limited", or "Tradamex life care limited", or any other name that may be approved by the Central Registration Center (CRC), Ministry of Corporate Affairs. This change is intended to align the company's corporate identity with its business activities, enhance brand visibility, and create a simpler identity. The change is contingent upon approval from the CRC and the company's shareholders, followed by amendments to the Memorandum and Articles of Association.

4. Alteration of Object Clause

The Board approved a proposal for the alteration of the Object Clause (Clause III (A)) of the company's Memorandum of Association (MOA), subject to shareholder and other regulatory approvals. The amendment seeks to insert new points 6 and 7 after the existing point 5 under the Main Objects. The new objects include:

  • Expanding business to include being general merchants, traders, international trade consultants, and export houses; dealing in all kinds of goods; and providing contract research organization (CRO), contract development and manufacturing organization (CDMO), and contract research and manufacturing services (CRAMS).
  • Establishing R&D centres and manufacturing facilities; and dealing in intellectual property rights, joint ventures, and technical collaborations.

The existing Main Object (point 5) involves carrying on the business of manufacturing, trading, and dealing in all kinds of chemicals, pharmaceuticals, nutraceuticals, and biotechnology products.

5. Notice of Extraordinary General Meeting (EGM)

The Board approved the Notice of an Extraordinary General Meeting (EGM) to be held through Video Conferencing (VC) to seek shareholder approval for the above resolutions.

6. Appointment of Scrutinizer

Mr. Brajesh Gupta, Practicing Company Secretary (Membership No. ACS 33070), proprietor of M/s. Brajesh Gupta & Co, was appointed as the Scrutinizer to conduct the e-voting process for the EGM.

7. Authorization

The Board authorized the Managing Director, Executive Director, or Company Secretary to send the notice of the EGM and to conduct the entire e-voting process in a fair and transparent manner.

This disclosure is made in compliance with SEBI Listing Regulations (LODR), including Regulation 30, and references SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.